ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Rituximab Interference in B-Cell Crossmatch: A Problem Solved

P. Malvezzi,1 O. Senoussi,2 T. Jouve,1 C. De Palma,2 L. Rostaing,1 B. Bardy,2 D. Masson.2

1Service de Néphrologie, Dialyse, Aphérèses et Transplantation, CHU Grenoble Alpes, Grenoble, France
2Laboratoire d'Histocompatibilité, EFS Rhone Alpes, Grenoble, France.

Meeting: 2018 American Transplant Congress

Abstract number: 542

Keywords: Antibodies, FACS analysis, Histocompatibility

Session Information

Date: Tuesday, June 5, 2018

Session Name: Concurrent Session: Kidney: Perioperative Considerations

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:42pm-5:54pm

Location: Room 303

Related Abstracts
  • Interference of Therapeutic Antibodies Used in Desensitization Protocols On Lymphocytotoxicity Crossmatch Results
  • Serum Treatment with Fetal Bovine Serum Significantly Increases Luminex-Based HLA Antibody Assay Specificity by Reducing Heterophile Antibody Interference

Background: Rituximab is commonly prescribed in ABO- or HLA-incompatible kidney transplantation. When used before transplant it interferes with B lymphocyte complement-dependent crossmatch (CDC CM) or FACS crossmatch (FACS CM) results thus rendering their interpretation impossible. This effect has been described up to 9 months following rituximab infusion.

We describe here a new method to abolish rituximab interference in both CDC CM and FACS CM.

Methods: We used an anti-rituximab mouse monoclonal antibody (10C5 clone, ABNOVA®) directed against the F(ab)2 fragment of rituximab. Normally this antibody is employed to dose rituximab by ELISA technique.

We tested different antibody concentrations in different settings (rituximab infusions 0 days to 270 days before CM; patients with and without class 1 and 2 HLA antibodies) and evaluated whether the interference of rituximab was abolished in FACS CM and CDC CM.

Results: A concentration of 0.17[micro]g/[micro]l of the 10C5 clone abolished completely false positive results in both CDC and FACS CM. 1[micro]l of 10C5 was thus added to 5[micro]l of serum for 15 minutes at room temperature, the CM was then performed. While these concentrations dilute the serum they did not nullify expected positive results. CDC and FACS CM stayed positive when donor specific HLA antibodies had a Luminex mean fluorescence intensity respectively >8000 and >4000.

Conclusion: We describe an easy, efficient and relatively inexpensive method to eliminate rituximab interference on CDC and FACS CM results.

CITATION INFORMATION: Malvezzi P., Senoussi O., Jouve T., De Palma C., Rostaing L., Bardy B., Masson D. Rituximab Interference in B-Cell Crossmatch: A Problem Solved Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Malvezzi P, Senoussi O, Jouve T, Palma CDe, Rostaing L, Bardy B, Masson D. Rituximab Interference in B-Cell Crossmatch: A Problem Solved [abstract]. https://atcmeetingabstracts.com/abstract/rituximab-interference-in-b-cell-crossmatch-a-problem-solved/. Accessed March 8, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Search
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.